The Duluth Clinic has worked for the past eighteen years to develop a multidisciplinary organization involved in the care of oncology patients and to function as a cancer research unit for the region. The Duluth Clinic was a founding member of the North Central Cancer Treatment Group in 1977 and has functioned as a COOP since 1984. During this time, the Duluth COOP has entered patients onto numerous clinical trials (2,735 to cancer treatment and 1,854 to cancer control and prevention), has assisted in the development of new programs, served as chair or co-chair on numerous protocols, and has presented at national meetings. All of the disciplines in oncology are brought together under the direction of the Duluth COOP. An excellent working relationship exists with the NCCTG, and data of unexcelled quality is generated as shown by past performance records. Geographically, the Duluth COOP is the only source providing the benefits of clinical cancer research to this large geographic area. The Thunder Bay Regional Cancer Centre component of the Duluth COOP covers a large area also. The plan is to continue to bring the advantages of clinical research to patients, to bring new programs (such as cancer prevention trials) to the area, and to continue to increase efforts in cancer prevention, cancer control, and cancer rehabilitation. The North Central Cancer Treatment Group functions as the primary research base with the secondary research bases being the Eastern Cooperative Oncology Group, the Children's Cancer Group, and the National Surgical Adjuvant Breast and Bowel Project. The goal of the Duluth COOP is to accrue over 180 patients per year onto cancer treatment protocols and over 250 patients to cancer control programs. By virtue of the already established programs and the commitment to quality, it is believed that a high level of productivity and quality can be maintained.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (16))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duluth Clinic, Ltd.
United States
Zip Code
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43
Dueck, A C; Singh, J; Atherton, P et al. (2015) Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int 26:1971-7
Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76
Dy, Grace K; Molina, Julian R; Qi, Yingwei et al. (2014) NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol 9:1146-53
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83

Showing the most recent 10 out of 172 publications